AVLN

28.7900.31%
DR

Douglas R. Carlson

CFO & Chief Business Officer

Mr. Douglas R. Carlson, also known as Doug, is Chief Financial Officer and Chief Business Officer of Avalyn Pharma Inc. from May 2024. He served as a Chief Operating and Financial Officer at Avenge Bio, Inc. Mr. Carlson served as Chief Operating Officer and Executive Vice President of Finance at Ikena Oncology, Inc. since February 2021 until February 18, 2022. He served as Chief Operating and Financial Officer at Avenge Bio, Inc. since joining the firm on February 22, 2022. He has experience with a multi-disciplinary background in corporate finance, venture capital, M&A, business development and commercial operations with both large and emerging growth healthcare companies. He had been Chief Operating Officer, Chief Compliance Officer and Executive Vice President of Finance at Ikena Oncology, Inc. since February 2021 until February 18, 2022. Mr. Carlson served as Chief Financial Officer of Ikena Oncology, Inc. since February 2019 until 2021.He served as Vice President of Commercial Operations, Corporate Strategy & Business Development of Collegium Pharmaceutical, Inc. since July 2018 until January 2019. Mr. Carlson served as Vice President of Commercial Operations of Collegium Pharmaceutical, Inc., since February 2018 until July 2018. Mr. Carlson served as Vice President of Corporate Development & Strategic Commercial Channels at Collegium Pharmaceutical, Inc. since January 28, 2017 until February 2018. Mr. Carlson served as a Vice President of Corporate Development at Collegium Pharmaceutical, Inc. since 2014 until January 28, 2017 and served as its Vice President of Business Development since April 03, 2013. Prior to joining Collegium, Mr. Carlson was Senior Director of Business Development at BTG International, Inc., where he was responsible for global specialty pharmaceutical M&A and licensing, from August 2011 to March 2013. Prior to BTG, Mr. Carlson was Senior Director and Head of Business Development for Lundbeck Inc. from December 2009 to August 2011. Prior to Lundbeck, Mr. Carlson was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., where he played an integral role in the sale of Ovation to H. Lundbeck A/S in March 2009. Mr. Carlson served as an Associate of FirstMark Capital, L.L.C. He joined FirstMark Capital in 2005 and focused on supporting investments in the healthcare sector. Previously, Mr. Carlson served as an Analyst at SG Cowen & Co., LLC. He worked in the healthcare investment-banking group focusing on the European biotechnology and specialty pharmaceutical sector. Mr. Carlson worked in the Boston healthcare investment-banking group focusing on the medical technology and life sciences sectors. He participated in all aspects of the execution of corporate finance transactions including initial public offerings, secondary offerings, private placements, equity-linked offerings, private investments in public equities (PIPES) and mergers and acquisitions. He served as a healthcare private equity associate at Pequot Capital Management and as a healthcare investment banking analyst at Cowen & Co. He received a B.A. from Trinity College in 2001 and completed a post-graduate program in Economics, International Banking and Accounting at University of Oxford.

Positions